Medical Devices

Camelot Wins Cue Health Omnichannel Media Buying & Planning Business

Camelot Wins

After a rigorous agency selection process, Camelot Strategic Marketing & Media has been chosen as media buying and planning agency for healthcare technology company Cue Health (“Cue”) as it aims to pioneer the digital transformation of healthcare, beginning with diagnostics.

The scope of Camelot’s work for Cue includes integrated media planning and buying across Cue’s growing diagnostic platform, aimed at providing better patient outcomes by delivering on the promise of timely, informed, and connected healthcare.

There is no question that Cue Health is on the leading edge of healthcare technology. We’re thrilled to align our passion for innovation, deep data and analytics, and creative digital media and marketing strategy to help drive their success into the future.”

Sam Bloom, CEO of Camelot Strategic Marketing & Media

Cue empowers people to live their healthiest lives by giving individuals and their healthcare providers easy access to lab-quality diagnostics anywhere, anytime, in a device that fits in the palm of the hand. Cue launched the first FDA-authorized COVID-19 molecular test for at-home and over-the-counter use as well as professional point-of-care use. Outside the U.S., Cue Health has received the CE mark in the European Union, Interim Order authorization from Health Canada, regulatory approval from India's Central Drugs Standard Control Organization, and PSAR authorization from Singapore’s Health Sciences Authority.

The company is developing future care offerings across several categories, including respiratory health, sexual health, cardiac and metabolic health, women's health, men's health, and chronic disease management.

Within the health and wellness space, Camelot also works with Baylor Scott & White Health, the largest not-for-profit​ healthcare system in Texas and one of the largest in the U.S., and Glo, a digital health platform and app providing live and on-demand yoga, meditation, Pilates and fitness classes.

About Camelot

Celebrating 40 years in the media and marketing industry, Dallas-based Camelot Strategic Marketing & Media, is a fact-based, bottom-up, independent agency with 150 employees in cities across the U.S. – including Dallas, New York, Los Angeles and Baltimore. We partner with a select group of the world’s biggest brands – from TurboTax to Whole Foods to Michaels – to provide media-agnostic, transparent, insight-driven media and marketing strategy and execution. 

Spotlight

Spotlight

Related News

Health Technology

Beckman Coulter Unveils DxC 500 AU Chemistry Analyzer, Expanding Portfolio with Proven Six Sigma Performance

Beckman Coulter Diagnostics | January 30, 2024

Beckman Coulter Diagnostics, a clinical diagnostics leader, will unveil its new DxC 500 AU Chemistry Analyzer, an automated clinical chemistry analyzer, at Medlab Middle East in Dubai, taking place February 5-8, 2024. The DxC 500 AU Chemistry Analyzer is one of several recent Beckman Coulter solutions designed to address the complete needs of healthcare systems that are looking to complement central hub laboratories by advancing the technology and capabilities of satellite and independent hospital laboratories. "Healthcare systems around the world are strategically adopting hub-and-spoke models for better efficiency and healthcare access," said Kathleen Orland, Senior Vice President, Business Unit, General Manager, Chemistry and Immunoassay for Beckman Coulter Diagnostics. "Hub-and-spoke clinical laboratory models optimize resources to improve access to testing services and enhance overall standardization for quality testing and positive impact on inventory and cost management across a health system. The new DxC 500 AU Chemistry Analyzer advances capabilities of spoked labs with a broad menu of high-quality assays that deliver consistent, commutable results across Beckman Coulter's AU clinical chemistry systems, positively impacting clinical decision-making and patient outcomes." The DxC 500 AU Chemistry Analyzer features advanced automation technology, onboard guided workflows, and standardized reagents for use across healthcare networks. Its menu of more than 120 assays has been independently and objectively verified for high quality Six Sigma performance, supporting confidence in clinical results, reducing QC trouble shooting and lab operational costs. "Our Six Sigma assessment has shown that the DxC 500 AU analyzer easily exceeds the demands of the new, more stringent CLIA 2024 performance specifications," stated Sten Westgard, Director of Client Services and Technology for Westgard QC. The DxC 500 AU Chemistry Analyzer is for in vitro diagnostic use only. It is available throughout North America and the Middle East. Global commercial availability is planned for March 2024. About Beckman Coulter. Inc. A global leader in advanced diagnostics, Beckman Coulter has challenged convention to elevate the diagnostic laboratory's role in improving patient health for more than 80 years. Our mission is to Relentlessly Reimagine Healthcare, One Diagnosis at a Time – and we do this by applying the power of science, technology and the passion and creativity of our teams. Our diagnostic solutions are used in complex clinical testing, and are found in hospitals, reference laboratories and physician office settings around the globe. We exist to deliver smarter, faster diagnostic solutions that move the needle forward from what's now to what's next. We seek to accelerate care with an extensive clinical menu, scalable lab automation technologies, insightful clinical informatics, and optimize lab performance services. Headquartered in Brea, Calif., with more than 11,000 global team members, Beckman Coulter Diagnostics is proud to be part of Danaher. Danaher is a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow's science and technology to improve human health. ©2024 Beckman Coulter. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.

Read More

Healthcare Analytics

SHL Medical partners with SteriPack Group to set up final assembly service

SHL Medical | January 24, 2024

SHL Medical, a world-leading solutions provider of advanced drug delivery systems and SteriPack Group, renowned global supplier of secondary packing and final assembly services to the pharmaceutical industry, enter a non-exclusive strategic partnership. Together, they aim to establish a pre-validated final assembly service at the SteriPack facility in Poland, enhancing the overall flexibility of supply chain strategies for their customers. In addition to SHL Medical's existing final assembly, labeling, and packaging­ services in the United States, this collaboration extends high-quality CMO options to Europe. Markus Puusepp, SHL Medical's Chief Growth Officer, expressed enthusiasm about the partnership, stating "This partnership is a significant addition to the Molly® platform value proposition. We share common values with SteriPack, from focus on the customer to a commitment to quality, making the decision to collaborate straightforward." Recognizing the importance of flexibility and time-to-market, especially in clinical production, the partnership with SteriPack will offer SHL Medical's customers highly flexible and personalized final assembly and packaging solutions. This is particularly beneficial for small batch handling in clinical supply and niche markets like rare diseases. Emphasizing the comprehensive capabilities of the Molly platform, SHL Medical aims to deliver right-sized solutions that ensure improved service, faster timelines, and a more streamlined supply chain for its diverse customer base. John Ward, SteriPack Group's VP Pharmaceutical Solutions commented "SteriPack Group looks forward to supporting SHL Medical and their customers in providing quality and flexible solutions to a fast- moving market. With an emphasis on creating service solutions designed around specific customer requirements, this partnership will make the process of working with the Molly® platform an easy decision." About SHL Medical As a world-leading solutions provider of advanced drug delivery systems, SHL Medical is the partner of choice for many leading pharma and biotech companies. Driven by its company purpose – Enabling Patients' Independence – SHL Medical offers patient-centric solutions for the design, development, and manufacturing of autoinjectors, pen injectors, as well as innovative specialty delivery systems for large-volume and high-viscosity formulations. It also offers final assembly, labeling, and packaging solutions for its drug delivery systems. In response to the rising trend in home therapy, SHL Medical has increased its developmental work in the digital healthcare sector to help improve the drug delivery ecosystem. Located across Switzerland, Taiwan, Sweden, and the US, SHL Medical's global team of experts collaborate seamlessly as one team in utilizing its comprehensive in-house manufacturing capabilities. Its solutions offer customization and optimization for each project while proactively weaving sustainability-driven measures into its designs and processes to contribute to a cleaner earth. About SteriPack Group SteriPack Group is a globally renowned contract packing and manufacturing organisation serving the pharmaceutical and medical device sectors respectively. With a strong emphasis on innovation, quality and compliance, SteriPack's services to the pharmaceutical industry include device design and development, final assembly, labelling, secondary packing, serialisation and aggregation of injectable formats including vials, pre-filled syringes, and autoinjectors. SteriPack's tailored customer-focused solutions make it an ideally suited supplier for small to medium-sized batch volumes required for a growing market of targeted therapies as well as clinical trials. Its proven capabilities in cleanroom assembly and labelling as well as secondary packing services for drug delivery systems and medical devices, combined with significant investment into growing cold chain storage capacity, have helped to make it a trusted partner to top global pharmaceutical companies.

Read More

Healthtech Security

Belong Health Launches Belong Medical Group to Help Health Plans and Healthcare Providers Address Gaps in Patient Care

Belong Health | January 10, 2024

Belong Health, a company dedicated to advancing patient-centered healthcare and reducing the cost of caring for underserved and complex populations, has announced the formation of Belong Medical Group to help its plan and provider partners address chronic gaps in patient care. Belong Medical Group supplements existing care infrastructure with virtual and community-based resources to care for every member – even those that are historically hard to reach. The team includes operators, clinicians, registered nurses, licensed clinical social workers and community health workers with extensive experience serving high-needs populations. Operating as a separate unit within Belong Health, Belong Medical Group is a transitional care organization that develops clinical programming and wraparound services to help plan partners, providers and provider groups care for members with chronic conditions during changes in their care plans. This improves patient outcomes while reducing overall costs. Bridging Gaps in Care Dual-eligible members require more specialty care, particularly in the areas of behavioral health and palliative care. Patients with mental illness combined with one or more chronic conditions average three-times the medical spend compared to patients without mental illness. Almost 45% of dual-eligible patients fall into this category. Belong Medical Group was built to serve high-needs patients, including the 11 million D-SNP members with complex issues, low incomes and pre-existing conditions, to improve outcomes and reduce costs. "The clinician shortage in the U.S. continues to worsen and existing care delivery models fail to meet the needs of patients, particularly those that are dually eligible,” said Belong Health CEO J. Patrick Foley. “Belong Medical Group is an innovative new model of care delivery that ensures the full integration of services, reduces fragmented care and drives operational efficiencies.” By providing transitional care, Belong Medical Group helps plans serving D-SNP beneficiaries and providers participating in ACO REACH by Bridging gaps in care through home-based and virtual specialty care services delivered by trusted members of Belong Medical Group’s Clinician and Care Management team. Ensuring equitable access to care in urban and rural areas by meeting patients where they are. Seamlessly integrating with the provider community to ensure that care is coordinated with their local provider for longitudinal care. Mental Health Connector Mental Health Connector is the first clinical solution available through Belong Medical Group. It serves patients without a current mental health provider or those with worsening chronic mental illness. These patients are identified during health risk assessments or hospital and ER admissions as having unmet mental health needs that require follow up. MVP Health Care, a regional not-for-profit health insurer serving New York and Vermont, is the first to offer Mental Health Connector to its members. "Since the inception of our pilot program with Belong Medical Group, we have witnessed notable improvements in the depression scores of our members who have sought care from our dedicated Mental Health Connector clinicians,” said Dr. Carl Cameron, MVP Health Care’s Chief Medical Officer. “This heartening progress reinforces our belief that collaborative efforts can truly shape a brighter future for those with diverse health care needs. Belong Health and Belong Medical Group stand as trusted partners who share our unwavering dedication to providing high-quality care to a complex population. We value their expertise and their commitment to working hand-in-hand with us, ensuring that our members receive the comprehensive support they need.” Patients enrolled in Mental Health Connector receive treatment from Belong Medical Group's clinicians for up to 90 days. The treatment plan put in place by Belong Medical Group’s psychiatrist or mental health specialist is then transitioned to either the patient's PCP for ongoing management, or to a longitudinal mental health clinician in the community. The goal is to both diagnose and address unmet mental health needs when patients need it most and then to triage the right level of care for the patient long-term once the issues are stabilized. This bridge to longitudinal care not only reduces the cost of care, it improves quality scores. “These programs are essential. We need to meet patients where they are to help them better stick to their care plans during transitional phases,” said Dr. Ramon Jacobs-Shaw, President of Belong Medical Group and Chief Clinical Officer at Belong Health. “Too many people, especially seniors and dually eligible individuals, have needs that are not met by the existing care delivery landscape. Belong Medical Group provides smarter and more targeted services to those patients to make sure their needs are fulfilled, improving outcomes and overall community health.” About Belong Health Belong Health provides a new approach to health insurance by establishing deep partnerships with providers and insurers. This innovative model empowers us to address the unfulfilled requirements of underserved and complex needs populations in a more patient-centric way. Through fully risk-bearing partnerships, Belong Health helps insurers deliver products that provide more collaborative care to the MA and D-SNP population. Belong Health is also an accredited Accountable Care Organization, dedicated to delivering value-based care for Medicare FFS. Our mission is to offer more compassionate, collaborative and smarter healthcare solutions for underserved and complex needs populations.

Read More